Thromboprophylaxis in arthroscopy: Survey of current practices in France and comparison with recommendations

Current national and international recommendations for thromboprophylaxis after arthroscopy procedures are not very detailed and likely not well known by surgeons. The aim of this study was to compare the daily clinical practices of members of the Francophone Arthroscopy Society (SFA) with current national and international recommendations.

The primary hypothesis was that the procedures adopted by more than 75% of SFA members conform to the national recommendations set out by the French Anesthesia and Intensive Care Society (SFAR) in effect at the time of this study.

A questionnaire was sent to members of the SFA asking three questions to capture their protocol (decision maker, prescriber, indication by procedure). Descriptive statistics were generated for each question. The percentage of prescription protocols conforming to each recommendation was compared to the target percentage (75% arbitrary threshold) by a Chi² test with a 5% threshold overall and for each type of procedure.

Thirty-five percent of the SFA members responded to the questionnaire. Overall, the compliance rate was 69%, which was significantly lower than the target (p<0.001). The compliance rate was significantly lower than the target for hip procedures, minor knee procedures and ankle procedures; each time, the prescription was excessive. The compliance rate was not different than the target for major knee procedures and upper limb procedures. The sole reason for non-compliance was a non-justified prescription.

Less than 75% of SFA members have adopted thromboprophylaxis protocols that comply with national SFAR recommendations in effect at the time of this study, with excessive prescription for procedures on the lower limb. Recent studies do not confirm that broadening of the prescription is justified. This large gap between published recommendations and current practices means that we should reconsider the relevance of current recommendations and re-evaluate the cost-benefit ratio of prescribing a drug-based thromboprophylaxis after arthroscopy surgery.

Level IV.